Literature DB >> 12759503

Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.

Anil Heroor1, Hiromasa Fujita, Susumu Sueyoshi, Toshiaki Tanaka, Uhi Toh, Takashi Mine, Hiroko Sasahara, Tomoya Sudo, Satoru Matono, Hideaki Yamana, Kazuo Shirouzu.   

Abstract

BACKGROUND: A definitive combined modality therapy superior to surgery alone has not yet been found for esophageal cancer. This retrospective study investigated the impact of postoperative adjuvant chemotherapy in patients who underwent curative (R0) esophagectomy with radical lymphadenectomy. STUDY
DESIGN: Two hundred and eleven patients with a squamous cell carcinoma in the thoracic esophagus who underwent transthoracic curative (R0) esophagectomy with radical lymphadenectomy, such as 3-field lymphadenectomy or total 2-field lymphadenectomy, between 1988 and 2000, were retrospectively reviewed. Ninety-four patients received postoperative chemotherapy - 2 courses of cisplatin (CDDP) plus fluorouracil (5-FU) or vindesine (VDS) - while the other 117 patients received surgery alone. The overall survival rate was compared between the two groups after being stratified by the numbers of the metastasis- positive lymph nodes.
RESULTS: Only in the subgroup of patients with 8 or more lymph nodes metastasis- positive, the surgery-with-postoperative-chemotherapy group had a significantly better survival than the surgery-alone group. No significant difference was found in survival between the two groups in any other stratified subgroup.
CONCLUSIONS: Postoperative adjuvant chemotherapy following curative (R0) esophagectomy with radical lymphadenectomy such as 3-field lymphadenectomy or total 2-field lymphadenectomy provided a benefit only in patients having metastasis in a large number - 8 or more - lymph nodes. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759503     DOI: 10.1159/000070390

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  10 in total

1.  Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases.

Authors:  Yaping Xu; Qixun Chen; Xinmin Yu; Ximing Zhou; Xiao Zheng; Weimin Mao
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

2.  Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.

Authors:  Satoru Matono; Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Hideaki Yamana; Kazuo Shirouzu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-01

3.  Occult solitary submucosal jejunal metastasis from esophageal carcinoma.

Authors:  Joerg Lindenmann; Franz Gollowitsch; Veronika Matzi; Christian Porubsky; Alfred Maier; Freyja Maria Smolle-Juettner
Journal:  World J Surg Oncol       Date:  2005-07-16       Impact factor: 2.754

4.  Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis.

Authors:  Shenglei Li; Hongtao Liu; Changying Diao; Xiaohui Wang; Ming Gao; Zongming Li; Lijie Song; Xianzheng Gao; Jing Han; Feng Wang; Wencai Li; Xinwei Han
Journal:  Oncotarget       Date:  2017-05-30

5.  Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

Authors:  Liangze Zhang; Weiwei Li; Xiao Lyu; Yan Song; Yousheng Mao; Shaoming Wang; Jing Huang
Journal:  Chin J Cancer Res       Date:  2017-04       Impact factor: 5.087

6.  Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis.

Authors:  Peiliang Zhao; Wanpu Yan; Hao Fu; Yao Lin; Ke-Neng Chen
Journal:  Thorac Cancer       Date:  2018-06-21       Impact factor: 3.500

7.  Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis.

Authors:  Qi Wang; Zixiang Wu; Tianwei Zhan; Shuai Fang; Sai Zhang; Gang Shen; Ming Wu
Journal:  BMC Cancer       Date:  2019-05-27       Impact factor: 4.638

8.  Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis.

Authors:  Yue Shao; Dan Chen; Liu Ye; Xin-Mei Wang; Qing-Chen Wu; Cheng Zhang
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

9.  Clinical Trends in Management of Locally Advanced ESCC: Real-World Evidence from a Large Single-Center Cohort Study.

Authors:  Yeong Jeong Jeon; Junsang Yoo; Jong Ho Cho; Young Mog Shim
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

10.  Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.

Authors:  Hui-Jiang Gao; Xiao-Bin Shang; Lei Gong; Hong-Dian Zhang; Peng Ren; Guo-Dong Shi; Yu-Cheng Wei; Zhen-Tao Yu
Journal:  Thorac Cancer       Date:  2019-12-11       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.